Jubilant Pharmova Share Price Falls Over 3% After Q1 FY27 Earnings Results: Total Income Up 17.6% YoY

On August 10, 2026, Jubilant Pharmova Limited released its consolidated unaudited financial results for the quarter ended June 30, 2026, as per the exchange filings.  

The company reported a total income of ₹2,249.30 crore and net profit of ₹56.40 crore for the quarter ended June 30, 2026. 

Jubilant Pharmova Q1 FY27 Earnings Results 

Jubilant Pharmova Limited recorded a total income of ₹2,249.30 crore for the quarter ended June 30, 2026. This figure represents an increase of 17.6% on a year-over-year basis compared to the ₹1,912.70 crore reported in the same quarter of the previous year.  

When compared to the preceding quarter ended March 31, 2026, where the income was ₹2,313.70 crore, the current total income reflects a decrease of 2.8%. 

The net profit or profit after tax for the quarter ended June 30, 2026, stood at ₹56.40 crore. This result marks a decline of 45.0% compared to the ₹102.50 crore profit recorded in the quarter ended June 30, 2025. 

Furthermore, the net profit decreased by 52.7% when measured against the ₹119.30 crore profit reported for the quarter ended March 31, 2026. 

Annual Financial Data for FY26 

For the financial year 2026, the company reported a total income of ₹8,345.60 crore. In the same period, the net profit or profit after tax for Jubilant Pharmova Limited reached a total of ₹397.50 crore. 

Executive Perspective 

Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia noted broad-based top-line expansion across all segments. Growth was particularly strong within the sterile injectables contract manufacturing segment. 

Operational margins dropped due to temporary product shortages in the core radiopharmaceuticals unit. Remediation outlays at the Montreal facility and elevated depreciation charges further compressed net profits. 

Segment Performance 

Radiopharmaceuticals posted ₹322 crore in revenue, while the radiopharmacy network added ₹700 crore. Allergy immunotherapy revenue grew by 18% to settle at ₹214 crore during the quarter. 

The sterile injectables division brought in ₹496 crore, boosted by expanded manufacturing capacity. Drug discovery operations climbed to ₹174 crore, whereas standard generic formulations registered ₹173 crore. 

Strategic Growth 

Management started commercial batch production of key medical imaging assets to address product shortages. Profit margins are projected to expand sequentially during the second half of the fiscal year. 

The corporation is spending over US$ 60 million to establish six additional manufacturing sites across America. This continuous network enhancement will cement their market position as a primary medical supplier. 

Jubilant Pharmova Share Price Performance 

As of August 11, 2026, at 10:31 AM, Jubilant Pharmova share price on NSE was trading at ₹929.90, down by 3.41% from the previous closing price. 

Read More: Amara Raja Energy & Mobility Share Price Falls Over 2% After Q1 FY27 Earnings Results: Total Income Up 23.8% YoY! 

Conclusion 

Jubilant Pharmova Limited reported a total income of ₹2,249.30 crore and net profit of ₹56.40 crore for the quarter ended June 30, 2026. Annual figures for FY26 recorded a total income of ₹8,345.60 crore and profit of ₹397.50 crore. 

For daily market updates and regular stock market news in Hindi, stay tuned to Angel One's share market news in Hindi. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities or companies mentioned are only examples and not recommendations. This does not constitute a personal recommendation or investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.